With the strengths available in developing processes for a wide variety of products, Symed has been able to match the needs of a wide range of therapeutic categories, particularly those in chronic areas. Some of the categories are:

1. Balsalazide Disodium Dihydrate

2. Bambuterol Hydrochloride

3. Brimonidine Tartarate

4. Carvedilol

5. Fluconazole

6. Itopride Hydrochloride

7. Ketorolac Tromethamine

8. Levocetirizine Dihydrochloride

9. Linezolid

10. Mosapride Citrate Dihydrate

11. Inositol Hexanicotinate

12. Racecadotril

13. Sibutramine Hydrochloride

14. Tamsulosine Hydrochloride

15. Thalidomide

16. Tizanidine Hydrochloride

17. Topiramate

18. Zaleplon

19. Ondansetron Hydrochloride Dihydrate

20. FENOTEROL HYDROBROMIDE 
                   
21. ESZOPICLONE 

22. GEMFIBROZIL 

23. HYDROXY CHLOROQUIN SULFATE 

24. IRON SORBITOL DEXTRIN CITRIC ACID COMPLEX 

25. IRON SUCROSE LIQUID 

26. IRON SUCROSE POWDER

27. ITOPRIDE

28. REBAMIPIDE 

29. LINEZOLID (FORM III ) 

30. HDROXYZINE HYDROCHLORIDE 

31. PREGABALIN 

32. RIMONABANT 

33. STANAZOLOL   

Symed Labs has also the capabilities to supply intermediates for a wide range of products.

* None of the products will be supplied to countries in which this could be in conflict with the existing patents. However, the final responsibility lies exclusively with the buyer.

Symed Labs is now in the process of exploring the possibilities of expanding of both its product and therapeutic ranges. It has the requisite competitive edge in achieving the target of becoming a leading player in the manufacture and marketing of the bulk actives.